



### Assistant Professor Saar Gill

Assistant Professor of Medicine. Director, Gill Laboratory, Center for Cellular Immunotherapies

Saar Gill obtained his medical degree from the University of Melbourne in Australia in 1999. He underwent internal medicine training at St Vincent's Hospital in Melbourne, followed by haematology training at the Peter MacCallum Cancer Centre and at the Royal Melbourne Hospital, which he completed in 2008. In 2008 he became a post-doctoral fellow at Stanford University, where he studied adoptive cellular therapy with NK cells. In 2011 Dr. Gill moved to the University of Pennsylvania where he did a BMT and Cellular Therapy fellowship under Dr David Porter and started

working in the laboratory with Dr. Carl June on chimeric antigen receptor T cells for the treatment of acute myeloid leukemia (AML). Dr Gill currently runs an independent research group focusing on the production of effective and safe CAR T cells for the treatment of hematologic malignancies such as leukemia and lymphoma.



### Professor Kwee Yong

KWEE YONG, MA, MBBS, PhD, FRCP, FRCPATH Professor of Clinical Haematology, University College London, London, UK

Professor Kwee Yong is Professor and Honorary Consultant in haematology at University College London. Professor Yong is Clinical and Academic Lead for myeloma at University College London Hospital (UCLH) and the North London Cancer Network. She heads a large specialist team at UCLH that includes consultants, research fellows, clinical nurse specialists, research nurses, clinical trial practitioners and data managers.

Professor Yong is Chief Investigator on national clinical trials in myeloma and has an interest in early phase studies employing new agents and treatment strategies. She also runs an active laboratory programme working on aspects of myeloma biology and the mechanisms of bone disease, which has received funding from Leukaemia & Lymphoma Research, the Kay Kendall Research Fund, The Wellcome Trust and Cancer Research UK.



### Professor Leif Bergsagel

P. Leif Bergsagel, MD

Grohne Professor of Therapeutics for Cancer Research Consultant, Mayo Clinic Arizona Professor of Medicine, Mayo Clinic College of Medicine

Dr. Leif Bergsagel is a Professor of Medicine for the Mayo Clinic College of Medicine, and a consultant in the Division of Hematology and Medical Oncology, Department of Internal Medicine, at Mayo Clinic in Arizona. He is the Principal Investigator of the Mayo Clinic SPORE in Multiple Myeloma.

Dr. Bergsagel's research interest focuses on molecular pathogenesis of multiple myeloma. Working together with his wife, Dr. Marta Chesi, he identified the recurrent chromosome translocations in multiple myeloma, and developed a novel transgenic mouse model that faithfully reproduces the genetic, phenotypic, clinical and therapeutic features of human myeloma. An active investigator in many clinical trials, he has led efforts to develop targeted therapy for multiple myeloma, starting with targeting the t(4;14) chromosome translocation that he identified.

## General Information

Wifi code: 96026

Full buffet breakfast is served in the Bella Restaurant from 7:30 to 9:00 am

Lunch is served in the foyer outside the Marmion Ballroom

Morning and afternoon teas in the foyer outside the Marmion Ballroom

Pre-dinner drinks in the foyer outside the Marmion Ballroom - 7:00pm Friday

Pre-dinner drinks in the Birrarung Room - 5:30pm Saturday

Dinner served in the Marmion Ballroom at 8:00 pm Friday & 7:00pm Saturday

All sessions are held in the Marmion Ballroom unless otherwise stated

Hotel bar opens at 4 pm daily until late

Checkout is 11 am on Sunday – bags may be stored in the Birrarung Room behind reception

The bus for Melbourne Airport leaves Sunday at 12:15 pm

For those feeling like some exercise there are signposted Yarra walking trails outside the hotel reception

For room and hotel queries please contact the front desk

For all conference /event related queries please ask Alex Dawson or Steve Roach  
For all speaker / presentation related queries please ask Hayley Beer or Jacqueline Tate

Myeloma Australia and the Medical and Scientific Advisory Group wish to acknowledge the support of the following organisations



# 2ND NATIONAL Myeloma Workshop

A workshop for clinicians and researchers on the pathophysiology, treatment and new ideas in multiple myeloma.

Friday 14 – Sunday 16 September, 2018

Yarra Valley Lodge, Chirnside Park, Victoria, Australia  
[www.yarravalleylodge.com](http://www.yarravalleylodge.com)



# 2nd National Myeloma Workshop

A workshop for clinicians and researchers on the pathophysiology, treatment and new ideas in multiple myeloma.



# PROGRAMME



Friday 14 – Sunday 16 September, 2018

Yarra Valley Lodge, Chirnside Park, Victoria, Australia  
www.yarrawalylodge.com

## DAY 1: Friday 14 September

16:00	Arrival of delegates	
19:00	Welcome Event	
20:00	Opening Session and Dinner Upcoming developments in multiple myeloma research: 2-5 year forecast	Chair: Prof Miles Prince Speakers: Prof Leif Bergsagel, A/Prof Saar Gill, Prof Kwee Yong

## DAY 2: Saturday 15 September

08:50 – 09:00	Welcome and Introduction - A/Prof Simon Harrison	
<b>SESSION 1:</b>	<b>Immunotherapy for multiple myeloma: CAR T</b>	<b>Chair A/Prof Simon Harrison</b>
09:00 – 09:30	Upsetting the apple cart: towards a paradigm shift in the treatment of multiple myeloma	A/Prof Saar Gill - University of Pennsylvania
09:30 – 10:00	Novel Australian CAR T cell targets in development	A/Prof Simon Harrison - Peter MacCallum Cancer Centre
10:00 – 10:30	Abstract Presentation x 2	TBA
10:30 – 11:00	Morning Tea	
<b>SESSION 2:</b>	<b>Immunotherapy: Antibodies and Beyond</b>	<b>Chair A/Prof Simon Harrison</b>
11:00 – 11:30	Antibodies, BiTES and checkpoints	Prof Kwee Yong - University College London
11:30 – 12:00	Dissecting the heterogeneity in terminal effector CD8+T cells in multiple myeloma - insights from CyTOF and single cell transcriptome analysis	Prof Joy Ho - Royal Prince Alfred Hospital
12:00 – 12:30	Abstract Presentation x 2	TBA
12:30 – 14:00	Lunch and Poster Viewing	

## DAY 2: Saturday 15 September... continued

<b>SESSION 3:</b>	<b>Plasma cell biology and the microenvironment</b>	<b>Chair Prof Andrew Zannettino</b>
14:00 – 14:30	Microenvironmental control of myeloma dormancy and growth	Prof Peter Croucher - Garvan Institute of Medical Research
14:30 – 14:45	Multi-day intravital imaging of blood cancer and plasma cell interactions with bone marrow microenvironments	A/Prof Edwin Hawkins - Walter and Eliza Hall Institute
14:45 – 15:00	Optimising immunotherapy in Vk*MYC myeloma	Dr Marta Chesi - Mayo Clinic
15:00 – 15:15	Understanding plasma cell diversity	Prof Stephen Nutt - Walter and Eliza Hall Institute
15:15 – 15:45	Afternoon Tea	
<b>SESSION 4:</b>	<b>Laurence Catley Memorial Lecture</b>	<b>Chair Prof Andrew Spencer</b>
15:45 – 16:45	Laurence Catley Memorial Lecture. Molecular pathogenesis of multiple myeloma: A plasma cell enhanceropathy	Prof Leif Bergsagel - Mayo Clinic
16:45 – 17:45	Presentation of plenary abstracts 4 x 15 mins	Prize Winners - TBA
17:45 – 19:00	Poster Viewing	

**19:00 Dinner + Awards**  
**Chair: A/Prof Peter Mollee**

20th Anniversary of Myeloma Australia - Stephen Roach  
Building a career as a clinician scientist:  
The Australian versus US Experience - A/Prof Saar Gill

## DAY 3: Sunday 16 September

<b>SESSION 5:</b>	<b>New Targets in multiple myeloma</b>	<b>Chair Prof Andrew Spencer</b>
08:30 – 09:00	Novel targets in multiple myeloma	Prof Leif Bergsagel - Mayo Clinic
09:00 – 9:30	Targeting myeloma-associated immunosuppression	Dr Kyohei Nakamura - QIMR Berghofer Medical Research Institute
<b>SESSION 6:</b>	<b>Case Study Reviews</b>	<b>Chair A/Prof Hang Quach</b>
9:30 – 10:15	Launch of Myeloma Australia's Guided Interactive Cases (MAGIC) program . Case study 1: Dr Slav Ninkovic Case study 2: Dr Myles Wright	Prof Leif Bergsagel, A/Prof Simon Harrison, Prof Joy Ho, Prof Andrew Zannettino
10:15 – 10:45	Morning Tea	
<b>SESSION 7:</b>	<b>Myeloma Registry &amp; Trials Update</b>	<b>Chair A/Prof Peter Mollee</b>
10:45 – 11:15	Update: The Australasian Myeloma Research Consortium (AMARC) & The Myeloma and Related Diseases Registry (MRDR)	Prof Andrew Spencer - Alfred Hospital
11:15 – 11:30	Update: The Australasian Leukaemia & Lymphoma Group (ALLG) trials	A/Prof Hang Quach - St Vincent's Hospital
11:30	Closing remarks	A/Prof Simon Harrison - Peter MacCallum Cancer Centre

